Can Psychedelics Improve Decision-Making?

Boston University

For the one-in-five Americans with a mental health condition, the options for treatment aren't too much different from what they were half a century ago. Most medicines for psychiatric disorders were first pioneered in the 1950s .

But new research from Boston University offers fresh insight on a class of drugs many hope can provide new relief for those suffering from depression and anxiety: psychedelics. The study found that psychedelics can improve certain decisions.

In the study, published in Science Advances, researchers trained mice to use sensory cues, pulses of light, to identify which of two sites held a reward. Untreated mice performed the task moderately well but made mistakes, such as returning to the same location regardless of the cues. After receiving psilocybin or ketamine, mice performed better, making fewer mistakes by relying less on habits and more on the relevant sensory cues.

While psychedelics have shown promise, how they alter the brain to produce their therapeutic and mind-altering effects is poorly understood. "These findings reveal how psychedelics reduce the reliance on habits and repetitive choices, which may explain part of their therapeutic effect," says Benjamin Scott, a BU College of Arts & Sciences assistant professor in the department of psychological and brain sciences who co-led the study with Steve Ramirez, an associate professor in the department of psychological and brain sciences.

Scott answered questions about the research findings and what this could mean for mental health.

Why is there so much current excitement among neuroscientists about psychedelics' potential to improve mental health treatment?

Psychedelic drugs show remarkable potential as therapeutics, providing rapid, long-lasting improvements in mood. For example, in patients with depression, studies have reported meaningful benefits after a single dose of psilocybin, and those benefits persist long after the acute effects of the drug. This is dramatically different than today's first-line drugs for depression, the Selective Serotonin Reuptake Inhibitors (SSRIs). SSRIs can take weeks before they become effective and often are prescribed chronically, so people need to be on these drugs for long periods of time to maintain the benefit. Finally, and most importantly, around 30% of individuals with depression are resistant to standard treatment, meaning they do not receive benefit from SSRIs. Thus, there is excitement that psychedelics could provide a benefit to these individuals.

What kinds of disorders could they one day help treat?

Classic psychedelics, like psilocybin, have been proposed as a treatment for depression, addiction, and forms of anxiety, including post-traumatic stress disorder. Ketamine is currently used to treat depression. As we learn more about the broader effects of psychedelics, the range of disorders may expand.

What do we know about how they change the brain? And what did you learn about those processes in your study?

We know a great deal about how psychedelics affect the nervous system. The effects are complex and occur at multiple levels. At the molecular level, psychedelics bind to receptors on neurons, glia, and possibly other cell types. Binding of the drugs to these receptors has cascading effects on the nervous system, altering cells, circuits, and brain activity. The specific changes depend upon the type of psychedelic.

Classic psychedelics, like psilocybin, target serotonin receptors (including 5-HT2A and 5-HT1A subtypes). By activating these receptors, classic psychedelics change cells in many ways: altering gene expression, plasticity, and communication with other cells. By changing the way these cells communicate, psychedelics alter the flow of information through the nervous system.

In contrast, ketamine is an atypical psychedelic (also called a dissociative psychedelic) and its mechanism of action is different. It is an antagonist of a specific glutamate receptor (the NMDA receptor). While the initial targets of ketamine and psilocybin are different, an important question is whether the downstream effects of psilocybin and ketamine converge on specific downstream circuits to mediate their behavioral effects.

The discovery we report in this paper is that these two drugs have similar pro-cognitive effects, at least in mice performing a simple task. Both drugs strengthen the influence of sensory evidence on choices and reduce the effect of bias. Thus, decisions became more accurate, guided by the immediate sensory environment of the animals and less influenced by other factors, like the bias to repeat the same choice over again.

What's happening in the brain—what's changing and what's not?

After mice were given psilocybin, the brain changes we observed were widespread yet subtle. Widespread because so many areas of the brain are affected: our experiments mapping brain-wide activity using genetic markers revealed that many brain regions changed their activity after drug administration. Subtle because the changes in brain activity were small relative to the effect of the tasks, their sensory cues, and rewards on the brain.

For example, we measured neural activity in the orbitofrontal cortex (OFC), a region of the brain thought to play a role in decision making and belief updating. Neurons in this region track signals related to sensory processing and decision making. In fact, you can predict when animals make their decision or whether they got the answer correct from the activity patterns in the OFC. After delivery of the drug, these activity patterns were largely preserved, suggesting that the psychedelics gently sculpt ongoing brain activity related to experience rather than completely altering it. This is consistent with models of psychedelic function, where an individual's mindset and the environmental conditions while taking the drug (so called "set and setting") are major drivers of the experience while under the drug.

You found the drugs helped subjects make more accurate choices and think more deliberatively, but were there negative consequences too?

Yes, we did observe potential negative consequences. We observed a tradeoff between speed and accuracy, so animals' decision accuracy improved but at the expense of time. Extrapolating on this, you could imagine that in situations where processing speed or reaction time is critical, for example, while driving or playing sports, these drugs could negatively affect performance.

What further research is needed before they can be used as therapeutics?

These drugs are already being used therapeutically. Ketamine has FDA approval and is already being widely used as a therapy for depression. Psilocybin has more restrictions for its use, but it has already been through clinical trials, so FDA approval is the next step. I'll note that even after these drugs are approved, they still need to be monitored for safety, as unexpected side effects can emerge in certain populations.

What new research avenues does this study open for you?

Next, we plan to identify the specific brain circuits responsible for the pro-cognitive effects of psychedelics and to discover ways to activate these circuits without the use of psilocybin and ketamine. This could lead to a deeper understanding of the neural mechanisms of cognition and the development of safer and more effective drugs in the future.

This is not a new approach. Using drugs to reveal fundamental mechanisms of biology is well-established. Many natural and synthetic drugs have served as discovery engines in neuroscience and cell biology for decades, revealing, for example, the existence of receptors and the basis of synaptic transmission in the nervous system. Using a similar playbook, we hope to use psychedelics to better understand the neural basis of higher cognitive function.

How does this fit with your broader research?

This work is directly related to our broader research program. Our labs study the neural mechanisms of learning, memory, perception, and cognition. We are hoping that these drugs will give us new insight into how our brains learn, adapt, and process information to make better decisions, and how these processes may be disrupted in neuropsychiatric disorders.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.